Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same

Patent 4364932 Issued on December 21, 1982. Estimated Expiration Date:

December 21, 1999. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Method of producing tumor antibodies
Patent #: 4172124
Issued on: 10/23/1979
Inventor: Koprowski , et al.

Method of producing antibodies
Patent #: 4196265
Issued on: 04/01/1980
Inventor: Koprowski , et al.

Method and apparatus for automated identification and enumeration of specified blood cell subclasses Patent #: 4284412
Issued on: 08/18/1981
Inventor: Hansen , et al.

Inventors

Assignee

Ortho Pharmaceutical Corporation

Application

No. 06/082515 filed on 10/09/1979

US Classes:

530/388.75, Binds T-lymphocytic cell or component or product thereof (e.g., T cell, thymocyte, T-lineage bone marrow cell, T-lymphoblastoid cell, T-lineage acute lymphoblastic leukemia cell, T-lymphocytic cell-surface antigen, etc.)424/154.1, T lymphocytic cell (e.g., T cell, thymocyte, etc.)435/70.21, Producing monoclonal antibody435/948, Using viruses or cell lines436/548, Monoclonal antibody514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI530/806, ANTIGENIC PEPTIDES OR PROTEINS530/808, MATERIALS AND PRODUCTS RELATED TO GENETIC ENGINEERING OR HYBRID OR FUSED CELL TECHNOLOGY, E.G., HYBRIDOMA, MONOCLONAL PRODUCTS, ETC.530/809, Fused cells, e.g., hybridoma, etc.530/868INVOLVING AUTOIMMUNITY, ALLERGY, IMMEDIATE HYPERSENSITIVITY, DELAYED HYPERSENSITIVITY, IMMUNOSUPPRESSION, OR IMMUNOTOLERANCE

Examiners

Primary: Fagelson, Anna P.

Attorney, Agent or Firm

Dellenbaugh; Geoffrey G.

International Classes

C07K 16/18 (20060101)
C07K 16/28 (20060101)
A61K 38/00 (20060101)

Abstract

Hybrid cell line for production of monoclonal antibody to an antigen found on normal human cytotoxic and suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Other References

Friedman, Immunology, vol. 31, 1976 pp. 759-765
Bobbrove, J. of Immunology, vol. 112, 1974 pp. 520-527
Brochier, Immunology, vol. 31, 1976 pp. 749-758
McMichael, Eur. J. Immunol., vol. 9, 1979 pp. 205-210
Lampson, J. of Supramolecular Structure, vol. 6, 1977 pp. 441-448
Iverson et al., Supra, pp. 192-194
Simpson et al., Supra, pp. 195-202
Ruddle, Supra, pp. 203-211
Taniguchi et al., Supra, pp. 212-216
Osborne et al., Supra, pp. 217-220
Saravia et al., Supra, pp. 224-231
Barnstable et al., Cell, vol. 14, May 1978, pp. 9-20
Fox, C & E News, Jan. 1, 1979, pp. 15-17
White et al., J Exp. Med., vol. 148, Sep. 1, 1978, pp. 664-673
Herzenberg et al. from Wier (Ed), Handbook of Exptl. Immunol., Blackwell, London, 3rd Ed., 1978 pp. 25.1-25.
Cosimi et al., Surgery, vol. 40, 1976, pp. 155-163
Parham et al., Nature, vol. 276, Nov., 1978 pp. 397-399
Melchers, (Ed), Lymph, Hybridoms, 2nd Workshop on Functional Properties of Tumors of T & B Lymph, Springer Verlag, Berlin/N.Y., 1978, pp. IX-XVIII
Yelton et al., Supra, pp. 1-7
Trucco et al., Supra, pp. 66-69
Levy et al., Supra, pp. 164-169
Hammerling et al., Supra, pp. 100-106
Kennett, SSIE Data Bank, Abstract of Grant, 5/77-4/79, Ab. No. 1 CA 189303
Herzenberg et al., SSIE Data Bank, Abstract of Grant, 9/77-7/79, Ab. No. 1 CA 468120
Williams, Cell, vol. 12, Nov. 1977, pp. 663-670, 672-673
Reinherz et al., (1), Proc. Nat. Acd. Sci. USA, vol. 76, Aug. 1979, pp. 4061-4065
Reinherz et al., (2) of Immunol., vol. 123, Sep. 1979, pp. 1312-1317
Kung, Science, vol. 206, Oct. 19, 1979, pp. 347-349